Masimo (NASDAQ:MASI – Get Free Report)‘s stock had its “hold” rating reaffirmed by equities research analysts at Needham & Company LLC in a research report issued on Wednesday,Benzinga reports.

After its longtime chief was ousted last year following a proxy battle, Masimo has now appointed a new CEO. | The medtech has ...

Telehealth and Telecare News since 2005 ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell ...

Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device maker said on Tuesday, months after longtime CEO and founder Joe Kiani was ousted in a bitter proxy battle with ...

Szyman led Edwards Lifesciences’ critical care unit for more than a decade before BD acquired the group last year. Her ...

(This Jan. 21 story has been corrected to fix the share price gain to 57% from 45% in paragraph 6) (Reuters) - Masimo named Becton Dickinson executive Katie Szyman as its top boss, the medical device ...

Former President Joe Biden jetted off to California hours after President Donald Trump's inauguration. The former president ...

Piper Sandler analyst Jason Bednar maintained a Buy rating on Masimo (MASI – Research Report) today and set a price target of $210.00. The ...

Masimo Taps Katie Szyman as Permanent CEO Szyman currently serves as the worldwide president of Advanced Patient Monitoring at Becton Dickinson and Co. Defense and Space Company Voyager Technologies ...

Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointe ...

Szyman, an industry leader with deep med-tech roots, to guide the company as it seeks to rebuild its reputation and revenues following a gritty two-year battle for control. Current CEO Michelle ...